Artemis Hospitals

artemishospitals.com

Artemis Hospitals is a healthcare venture, launched in 2007, by the promoters of the Apollo Tyres Group. Artemis is the first hospital in Gurgaon to be accredited by JCI and NABH. Designed as one of the most advanced in India, Artemis provides an in-depth expertise in the sphere of advanced medical & surgical interventions, comprehensive mix of inpatient and outpatient services. Artemis aims to provide excellent medical care in a compassionate environment and a practice dedicated to pioneering research, empowering the health care professionals and the diverse communities we serve. The clinical procedures followed in the hospital are technologically advanced and supervised by distinguished doctors of international repute. Our endeavor to deliver standard-setting medical care is lead by the needs of the patient; our exceptional medical facilities and unmatched responsiveness has made us one of the most revered hospitals in the country.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

SMALL MOLECULES LEAD IN RECENT NEW DRUG APPROVALS

DCAT Value Chain Insights | February 05, 2020

news image

Small molecules still lead over biologics in recent drug approvals, accounting for nearly three-fourths of drug approvals over the past several years, but will small molecules' dominance continue? DCAT Value Chain Insights takes an inside look. One measure to evaluate the role of small molecules versus biologics is to look how they have fared in recent approvals of new molecular entities (NMEs) by the US Food and Drug Administration’s Center for Drug Evaluation and Research. Between 20...

Read More

ALTO, A PHARMACY START-UP, JUST RAISED $250 MILLION FROM SOFTBANK’S VISION FUND 2 AND OTHERS

CNBC: | January 30, 2020

news image

Alto Pharmacy has raised $250 million from investors including SoftBank’s second Vision Fund, three people familiar with the matter told CNBC. The investment has already been approved by the Vision Fund’s investment committee, meaning it’s a done deal, the sources said. It also marks one of the first handful of known bets from the SoftBank’s new fund. The deal values the company at more than $700 million, according to one of the people. SoftBank’s Vision Fund has al...

Read More

VIEWS AND ANALYSIS, PHARMACY MARKET

ALTRO PHARMACEUTICALS TEAMS UP WITH LSPEDIA TO PROVIDE CUTTING-EDGE TECHNOLOGY FOR FDA DSCSA COMPLIANCE

PRNewswire | July 31, 2023

news image

LSPedia, a leading SaaS provider specializing in product traceability solutions for the pharmaceutical industry, has partnered with Altro Pharmaceuticals, enabling Altro customers to easily comply with the Drug Supply Chain Security Act (DSCSA) ahead of the FDA's final deadline on November 27, 2023. Altro provides expertise and services to pharmaceutical manufacturers and wholesale distributors, helping them expand their businesses, streamline supply chain operations, increa...

Read More

Business Insights

QHP CAPITAL ACQUIRES LEXITAS PHARMA SERVICES

Lexitas and QHP Capital | July 08, 2022

news image

QHP Capital the management company for NovaQuest Private Equity announced its acquisition of Lexitas Pharma Services a full-service ophthalmology contract research organization supporting biopharmaceutical and medical device clinical trials. Since 2011, Lexitas has provided clinical trial and medical strategy solutions to biopharmaceutical and medical device companies developing ophthalmic products. The Company provides end-to-end support and development expertise in the ant...

Read More
news image

SMALL MOLECULES LEAD IN RECENT NEW DRUG APPROVALS

DCAT Value Chain Insights | February 05, 2020

Small molecules still lead over biologics in recent drug approvals, accounting for nearly three-fourths of drug approvals over the past several years, but will small molecules' dominance continue? DCAT Value Chain Insights takes an inside look. One measure to evaluate the role of small molecules versus biologics is to look how they have fared in recent approvals of new molecular entities (NMEs) by the US Food and Drug Administration’s Center for Drug Evaluation and Research. Between 20...

Read More
news image

ALTO, A PHARMACY START-UP, JUST RAISED $250 MILLION FROM SOFTBANK’S VISION FUND 2 AND OTHERS

CNBC: | January 30, 2020

Alto Pharmacy has raised $250 million from investors including SoftBank’s second Vision Fund, three people familiar with the matter told CNBC. The investment has already been approved by the Vision Fund’s investment committee, meaning it’s a done deal, the sources said. It also marks one of the first handful of known bets from the SoftBank’s new fund. The deal values the company at more than $700 million, according to one of the people. SoftBank’s Vision Fund has al...

Read More
news image

VIEWS AND ANALYSIS, PHARMACY MARKET

ALTRO PHARMACEUTICALS TEAMS UP WITH LSPEDIA TO PROVIDE CUTTING-EDGE TECHNOLOGY FOR FDA DSCSA COMPLIANCE

PRNewswire | July 31, 2023

LSPedia, a leading SaaS provider specializing in product traceability solutions for the pharmaceutical industry, has partnered with Altro Pharmaceuticals, enabling Altro customers to easily comply with the Drug Supply Chain Security Act (DSCSA) ahead of the FDA's final deadline on November 27, 2023. Altro provides expertise and services to pharmaceutical manufacturers and wholesale distributors, helping them expand their businesses, streamline supply chain operations, increa...

Read More
news image

Business Insights

QHP CAPITAL ACQUIRES LEXITAS PHARMA SERVICES

Lexitas and QHP Capital | July 08, 2022

QHP Capital the management company for NovaQuest Private Equity announced its acquisition of Lexitas Pharma Services a full-service ophthalmology contract research organization supporting biopharmaceutical and medical device clinical trials. Since 2011, Lexitas has provided clinical trial and medical strategy solutions to biopharmaceutical and medical device companies developing ophthalmic products. The Company provides end-to-end support and development expertise in the ant...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us